Roche’s GLP‑1/GIP receptor agonist CT‑388 demonstrated strong efficacy in patients with obesity | iPharmaCenter
Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity. A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% at 48 weeks at the highest dose tested (24 mg), without reaching a weight loss plateau 54% of participants on the 24 mg dose achieved resolution of obesity (BMI <30 kg/m2) vs. 13% in the placebo group. CT-388 demonstrated a safety and tol
NICE greenlights Dupixent as add-on therapy for uncontrolled COPD with raised eosinophils in England, marking first targeted biologic for this indication | iPharmaCenter
The UK's National Institute for Health and Care Excellence (NICE) issued final draft guidance on January 26, 2026, recommending Dupixent (dupilumab ; Sanofi/Regeneron) for adults with moderate-to-severe chronic obstructive pulmonary disease (COPD) that remains uncontrolled despite maximal inhaled therapy. Eligible patients must show elevated blood eosinophils (≥300 cells/μL), indicating type 2 inflammation, and have had ≥1 severe or ≥2 moderate exacerbations in the prior year
Amlitelimab meets primary endpoints in Phase 3 atopic dermatitis trials, enabling Sanofi regulatory submissions | iPharmaCenter
Sanofi has reported new phase 3 and phase 2 data indicating that amlitelimab continues to build its profile as a potential treatment option for adolescents and adults with moderate-to-severe atopic dermatitis. Amlitelimab: Phase 3 program overview Amlitelimab is a fully human, non–T‑cell–depleting monoclonal antibody that selectively targets OX40 ligand, designed to modulate immune pathways involved in atopic dermatitis. The late-stage program includes three global studies, C
SFDA approved the registration of Anktiva for selected bladder and lung cancer indications | iPharmaCenter
Saudi Food and Drug Authority (SFDA) has approved the registration of Anktiva (nogapendekin alfa inbakicept) for selected bladder and lung cancer indications, introducing a new immunotherapy option for patients with limited treatment choices. Under the new authorization, Anktiva may be used for adult patients with metastatic non‑small cell lung cancer whose disease has progressed after standard systemic therapies, in combination with immune checkpoint inhibitors. SFDA has als
FDA clears one‑minute subcutaneous mosunetuzumab for heavily pretreated follicular lymphoma | iPharmaCenter
The US Food and Drug Administration has authorised a new under‑the‑skin version of the CD20xCD3 bispecific antibody mosunetuzumab for adults with relapsed or refractory follicular lymphoma after two or more previous systemic treatments. This subcutaneous regimen, known as Lunsumio VELO, received accelerated approval based on phase I/II data from the GO29781 trial, with continued approval potentially dependent on confirmation of clinical benefit in a follow‑up study. iPharmaCe
China Approves Myqorzo and Redemplo, Expanding Options in Hypertrophic Cardiomyopathy and Familial Chylomicronaemia Syndrome | iPharmaCenter
China’s National Medical Products Administration has authorised two innovative therapies licensed by Sanofi, strengthening treatment options in serious cardiovascular and lipid disorders. Myqorzo (aficamten) has been approved for adults with obstructive hypertrophic cardiomyopathy, while Redemplo (plozasiran) has been cleared to reduce triglyceride levels in adults with familial chylomicronaemia syndrome who require dietary management. iPharmaCenter Consulting: Find services